Prestige Consumer Healthcare posts strong Q2 revenue growth and raises FY 2027 guidance

Prestige Consumer Healthcare reported second‑quarter fiscal 2027 revenue of $336.3 million, a 22.7% year‑over‑year increase driven by recent acquisitions and brand strength. Adjusted diluted earnings per share rose to $1.13, up about 6% from the prior year. The company lifted its full‑year 2027 outlook to $1.28 billion‑$1.29 billion of revenue and $4.48‑$4.55 of adjusted diluted EPS. Management said the results confirm the integration of the Breathe Right and LaCorium acquisitions and support continued free‑cash‑flow generation.

The higher revenue and earnings guidance suggest stronger cash flow, which the company plans to use for debt reduction (the out‑of‑scope share‑repurchase authorization is $90 million). Investors should adjust their valuation models to reflect the raised FY 2027 targets.

  • 1Q2 revenue was $336.3 million, up 22.7% YoY.
  • 2Adjusted diluted EPS for the quarter was $1.13.
  • 3Full‑year 2027 revenue guidance was raised to $1.28 billion‑$1.29 billion.
  • 4Full‑year 2027 adjusted diluted EPS guidance was raised to $4.48‑$4.55.
  • 5EBITDA margin for the quarter was reported at 34%.

Sources